FIELD: medicine.
SUBSTANCE: invention relates to medicine, namely to neurology. Essence of the invention consists in the erythrocyte magnesium level (mmol/l) and the level of matrix metalloproteinase I (ng/ml), wherein the examination is carried out twice a month, calculating the ratio of the level of matrix metalloproteinase I to the erythrocyte magnesium level, with increase or decrease of this ratio by 25 % and more, high risk of neurological complications in patients with blood diseases is detected, otherwise the risk of developing neurological complications in patients with blood diseases is insignificant.
EFFECT: invention can be used for assessing the risk of neurological complications in patients with blood diseases.
1 cl, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR ASSESSING RISK OF DEVELOPING ADVERSE POST-TRAUMATIC NEUROPATHY IN DIAPHYSEAL FRACTURES OF HUMERUS | 2019 |
|
RU2711438C1 |
| METHOD FOR ASSESSING RISK OF DEVELOPING COMPLICATIONS IN THE LONG-TERM POSTOPERATIVE PERIOD IN PATIENTS WITH SIGNS OF CONNECTIVE TISSUE DYSPLASIA | 2018 |
|
RU2664455C1 |
| METHOD FOR EARLY POSTOPERATIVE RISK ASSESSMENT IN PATIENTS WITH CONNECTIVE TISSUE DYSPLASIA | 2018 |
|
RU2706537C1 |
| DIAGNOSTIC TECHNIQUE FOR CONNECTIVE TISSUE DYSPLASIA IN NEWBORNS | 2020 |
|
RU2741699C1 |
| METHOD FOR PREVENTIVE DIAGNOSIS OF THE RISK OF REDUCING THE LEVEL OF HEALTH OF ADOLESCENT GIRLS | 2021 |
|
RU2782556C1 |
| METHOD FOR ASSESSING THE RISK OF DEVELOPING COSMETIC DEFECTS IN THE POSTOPERATIVE WOUND IN SURGICAL PATIENTS WITH CONNECTIVE TISSUE DYSPLASIA | 2019 |
|
RU2708455C1 |
| METHOD FOR ASSESSMENT OF RISK OF REDUCTION IN HEALTH LEVEL IN CHILDREN OF FIRST YEAR OF LIFE | 2021 |
|
RU2783674C1 |
| METHOD FOR ASSESSING RISK OF SEVERE PHYSIOLOGICAL JAUNDICE OF NEWBORNS | 2020 |
|
RU2750977C1 |
| METHOD FOR EARLY PREDICTION OF CHRONICITY OF PAIN IN HERPES ZOSTER | 2019 |
|
RU2718282C1 |
| METHOD FOR ASSESSING THE RISK OF ADVERSE OUTCOME IN CHILDREN WITH PERIPHERAL PARESIS | 2021 |
|
RU2779561C1 |
